irbesartan mylan 75 milligram tablets
mcdermott laboratories ltd t/a gerard laboratories - irbesartan - tablets - 75 milligram
irbesartan mylan 150 milligram tablets
mcdermott laboratories ltd t/a gerard laboratories - irbesartan - tablets - 150 milligram
irbesartan mylan 300 milligram tablets
mcdermott laboratories ltd t/a gerard laboratories - irbesartan - tablets - 300 milligram
mylan-clopidogrel tablet
mylan pharmaceuticals ulc - clopidogrel (clopidogrel bisulfate) - tablet - 300mg - clopidogrel (clopidogrel bisulfate) 300mg - platelet aggregation inhibitors
irbesartan mylan
mcdermott laboratories ltd t/a gerard laboratories - irbesartan - tablets - 75 milligram
irbesartan mylan
mcdermott laboratories ltd t/a gerard laboratories - irbesartan - tablets - 150 milligram
irbesartan mylan
mcdermott laboratories ltd t/a gerard laboratories - irbesartan - tablets - 300 milligram
irbesartan hct mylan 300/25 irbesartan/hydrochlorothiazide 300/25 mg tablet blister pack
alphapharm pty ltd - hydrochlorothiazide,irbesartan -
irbesartan and hydrochlorothiazide tablet
west-ward pharmaceuticals corp. - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - irbesartan 150 mg - irbesartan and hydrochlorothiazide is indicated for the treatment of hypertension. irbesartan and hydrochlorothiazide may be used in patients whose blood pressure is not adequately controlled on monotherapy. irbesartan and hydrochlorothiazide may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. the choice of irbesartan and hydrochlorothiazide as initial therapy for hypertension should be based on an assessment of potential benefits and risks. patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. the decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy
irbesartan and hydrochlorothiazide tablet, film coated
hisun pharmaceuticals usa inc. - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - irbesartan 150 mg - irbesartan and hydrochlorothiazide tablets usp are indicated for the treatment of hypertension. irbesartan and hydrochlorothiazide tablets usp may be used in patients whose blood pressure is not adequately controlled on monotherapy. irbesartan and hydrochlorothiazide tablets usp may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. the choice of irbesartan and hydrochlorothiazide tablets usp as initial therapy for hypertension should be based on an assessment of potential benefits and risks. patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. the decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving